It is valuable to determine the presence of precursor T cells specific for HER-3 peptides in the HNSCC patients for confirming the immunogenicity of HER-3 and predicting the potential use of this peptide as a cancer vaccine. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.